An observational study in Stage IIIA Non-small Cell Lung Cancer, sponsored by Fundación GECP. Recruiting at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Fundación GECP · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP — 8 open to participants now, 13 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fundación GECP.
Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, this one is one of 5 that started in 2021, is one of 5 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 9th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP are open now, in 1 country. Recruiting first, the newest first:
Fundación GECP · Sites in Spain
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 63 across the 13 interventional studies, 118 across the 5 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación GECP is the lead sponsor of 25 studies on the registry; 8 are open to participants now.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04223596Fundación GECPClinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | 2026-11-30 |
| NCT05382052Fundación GECPStudy of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment | 2026-12-30 |
| NCT05012254Fundación GECPNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | 2027-10-15 |
| NCT06634199Fundación GECPStudy of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients | 2027-11-04 |
| NCT03838159Fundación GECPNADIM II: Neo-Adjuvant Immunotherapy | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.
This is a non-interventional, observational, multicenter and retrospective study that will not under any circumstances interfere in the physician's normal clinical practice. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry (TTR) data base and the data from stage IIIA clinical trials case report forms, it does not entail any diagnostic or therapeutic procedure outside of normal clinical practice.
The primary objective is to assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.
It is estimated that around 15-20 Spanish sites are enrolling patients with these characteristics in the TTR or in the stage IIIA clinical trials of the Fundación GECP.
Pathologists and physician's of these sites will be invited to participate in the PLANET study as all cases will be clinical-pathologically re-evaluated to reach the study objectives. Each pathologist will re-evaluate the specimens from the selected patients under common criteria.The sample size would be 150 patients enrolled in the study.
The study will include all resectable stage IIIA patients who have received platinum-based neoadjuvant treatment and surgery and that were diagnosed as stage IIIA from 2010 to 2017.The cohort of patients identified for the current study will be based on a portion of patients included in the Thoracic Tumor Registry (TTR) and in stage IIIA clinical trials approved by Spanish Health Authorities which the sponsor is Fundación GECP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
Drug: Cisplatin · Drug: Carboplatin
Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Also known as: Cis-diammine-dichloroplatinum, Platinol
Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Also known as: Paraplatin
To assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.
Pathological response will be assessed as complete pathological response, major pathological response (defined as ≤10% of viable tumor cells) and incomplete pathological response.
Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months
To describe the percentage of residual viable tumor in this population of patients under common criteria
A) No response or more than 70% of viable tumor: Lymph node major pathological response negative (LN-MPR)- B) ≤70% of viable tumor cells: Lymph node major pathological response positive (LN-MPR)+ C) No evidence of any viable tumor (including primary tumor): Complete pathological response
Time frame: From the end of neoadjuvant treatment until the last follow up or death,assessed up to 45 months
To describe the histopathological changes within tumor bed associated to tumor response
Types of histopathological changes within tumor bed: fibrosis, lymphoid aggregates and others
Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months
To correlate pathological response and post-surgical complications
Pathological response will be assessed as complete pathological response, major pathological response (defined as ≤10% of viable tumor cells) and incomplete pathological response.
Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months
To describe the relation between nodal downstaging after neoadjuvant treatment and overall survival
Downstaging after surgery is a reduction in the stage of a cancer. Overall Survival defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.
Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months
Plan to share: No
Started Dec 2021 (actual). Primary completion is estimated for Apr 2028, 75 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Fundación GECP